Marco Meglio

In addition to having a lowered number of headache days, around 20% of patients transformed to low-frequency, episodic migraine on follow-up.

Selumetinib becomes the first therapy approved for pediatric patients with Neurofibromatosis type 1.

Incorporating remote electrical neuromodulation into the standard of care may have a positive impact on migraine management by reducing the reliance on acute medications.

The probability of relapse and disability progression during pregnancy was associated with time when natalizumab was stopped and number of relapses in the year before natalizumab treatment.

The drug successfully demonstrated an ability to reduce mutant huntingtin protein, but the clinical benefits of that effect are yet to be determined.

The director of Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, and principal investigator in the DEVOTE study discussed details of the trial and its potential impact for patients with spinal muscular atrophy.

Eligible commercially insured patients may pay as little as $5 per infusion every 3 months for eptinezumab through the VYEPTI Copay Assistance Program, according to Lundbeck.

Phase 3 INTERCEPT data suggest the agent is successful in migraine treatment, and an NDA submission of AXS-07 in the acute treatment of migraine is on track for Q4 2020.

Patients with migraine may order the pain relief medication device directly to their homes through UpScript’s telemedicine platform.

The >50% responder rate was similar between children and adults according to data from a meta-analysis of 7 clinical trials of topiramate, perampanel, and lamotrigine.

The phase 3 study will commence following the results of the phase 2b/3 AB10015 study, in which masitinib significantly slowed disease progression in combination with riluzole.

Treatment with in-hospital remote ischemic perconditioning did not reduce brain infarction volume growth and showed similar mortality rates for the intervention and control groups in the RESCUE-BRAIN study.

Cognitive change over time was similar in both the aspirin and placebo groups.

Full data from the ARCADE study of Ovid’s soticlestat is expected to be released in the first quarter of 2021.

Systemic blood pressure of

Study results suggest that unexplained seizures in older adults may also be a first sign of a neurodegenerative disease.

Researchers noted at least a 50% reduction from baseline in mean number of moderate to severe migraine days per month in 48% of the rimegepant group.

Data suggests that the longer the extubation time following mechanical thrombectomy, the higher the risk of unfavorable outcomes and pneumonia.

By the end of the open-label extension, 15-17% of patients showed clinically meaningful first response with eculizumab treatment.

Patients with spinal muscular atrophy maintained the ability to thrive and achieved motor milestones previously unseen in natural history studies.

In addition to no-charge testing, patients may have access to the Detect Muscular Dystrophy program, a counseling program designed to aid health decisions and follow-up care.

Nearly all patients in this cohort achieved a clinically meaningful >3-point increase during the study period, demonstrating a consistent response to the gene therapy.

No unexpected safety signals were reported in the post hoc analysis.

After meeting co-primary end points of pain freedom and freedom from the most bothersome symptom, the acute migraine agent has been cleared for a phase 3 trial by the FDA.

Eligible patients with Duchenne muscular dystrophy may receive the drug while it is under priority review by the FDA.

Patients with multiple sclerosis who reported cannabis use noted that it was helpful in relieving pain, as well as other symptoms, such as sleep, depression, anxiety, and/or stress.

The risk of relapse was higher with treatment of mycophenolate mofetil in patients with neuromyelitis optica spectrum disorder and other first-line immunosuppressants, compared to treatment with rituximab.

Eton Pharmaceuticals plans to submit a new drug application for ET-101 in the third quarter of 2020, anticipating its formulation to be the first approved oral topiramate solution.

A combination of different physical therapy interventions designed to improve fitness, motor function, and gait are all recommended when guiding clinical practice for patients with Huntington disease.

The ongoing phase 3 trial of the Biohaven drug is expected to be completed October 20, 2021.